CM
VERV

Caption Management’s Verve Therapeutics VERV Stock Holding History

Caption Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-72,500
Closed -$1.01M – 1690
2023
Q4 		$1.01M Sell
72,500
-55,000
-43% -$682K 0.01% 802
2023
Q3 		$1.69M Buy
127,500
+105,000
+467% +$1.69M 0.03% 630
2023
Q2 		$422K Sell
22,500
-7,500
-25% -$125K 0.01% 850
2023
Q1 		$433K Buy
+30,000
New +$587K 0.01% 817

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Caption Management's VERV Position: Q1 2024 in Review

Caption Management sold out of Verve Therapeutics (VERV) in Q1 2024, closing a stake of 21,324 shares — an estimated $297K sold.

Caption Management first reported a position in VERV in Q3 2022 and held it in 3 quarters. The position peaked at $342K in Q3 2022. 163 funds tracked by Wall St. Rank hold VERV as of Q1 2024.

  • Caption Management reported no remaining Verve Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Caption Management sold 21,324 Verve Therapeutics shares in Q1 2024, an estimated $297K.
  • Caption Management first reported a position in Verve Therapeutics in Q3 2022 and held it in 3 quarters.
  • Caption Management's Verve Therapeutics position peaked at $342K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2024.

Based on Caption Management's 13F filing for Q1 2024, filed 15 May 2024.